Physician profile
Shawn E Bailey
NPI 1447363585
$9,222.25
in general payments reported to CMS, 2019-2025
42 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $1,422 · 2021: $2,130 · 2022: $1,970 · 2023: $1,080 · 2024: $213 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $916.28 | 2019-2023 | Farxiga, Lokelma |
| Amgen INC. | $703.62 | 2019-2024 | Evenity, Prolia, Otezla |
| Nestle Healthcare Nutrition INC. | $603.92 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.87 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $527.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $515.51 | 2019-2023 | |
| Abbvie INC. | $481.59 | 2021-2023 | Qulipta, Ubrelvy, Vraylar |
| Astellas Pharma US INC | $382.40 | 2019-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $350.74 | 2019-2023 | |
| Novo Nordisk INC | $344.80 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $324.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $317.97 | 2019-2022 | |
| Glaxosmithkline, LLC. | $306.96 | 2019-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.18 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $261.91 | 2019-2023 | Mounjaro |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.